

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)



(10) International Publication Number
WO 2025/106386 A1

(51) International Patent Classification:

A61P 9/10 (2006.01) C07K 7/64 (2006.01)
A61P 29/00 (2006.01) A61K 38/00 (2006.01)

(21) International Application Number:

PCT/US2024/055428

(22) International Filing Date:

12 November 2024 (12.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/598,567 14 November 2023 (14.11.2023) US
63/717,339 07 November 2024 (07.11.2024) US

(71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(72) Inventors: **CRUZ, Faben A.**; 126 East Lincoln Avenue,
Rahway, New Jersey 07065 (US). **FENG, Danqing**; 126
East Lincoln Avenue, Rahway, New Jersey 07065 (US).
GUO, Yan; 126 East Lincoln Avenue, Rahway, New Jer-
sey 07065 (US). **HANISAK, Jennifer**; 126 East Lincoln
Avenue, Rahway, New Jersey 07065 (US). **HICKEY, Jen-
nifer L.**; 126 East Lincoln Avenue, Rahway, New Jersey
07065 (US). **KALYANI, Dipannita**; 126 East Lincoln Ave-
nue, Rahway, New Jersey 07065 (US). **KEKEC, Ahmet**;
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).
LI, Bing; 126 East Lincoln Avenue, Rahway, New Jersey
07065 (US). **LO, Michael Man-Chu**; 126 East Lincoln Ave-
nue, Rahway, New Jersey 07065 (US). **PISSARNITSKI,
Dmitri A.**; 126 East Lincoln Avenue, Rahway, New Jersey
07065 (US). **PLUMMER, Christopher W.**; 126 East Lin-
coln Avenue, Rahway, New Jersey 07065 (US). **TRUONG,
Quang T.**; 126 East Lincoln Avenue, Rahway, New Jer-

sey 07065 (US). **COLARUSSO, Stefania**; Via Pontina, km
30,600, 00040 Pomezia (RM) (IT).

(74) Agent: **MEADE, Eric A.**; 126 East Lincoln Avenue, Rah-
way, New Jersey 07065 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MU, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA



(57) Abstract: Provided are compounds of the Formula (I), or their
pharmaceutically acceptable salts, wherein X^1 , X^2 , X^3 , R^1 - R^9 , R^A ,
 R^B , R^D , A^1 , A^2 , and subscripts t and w are as herein described. For-
mula (I). The compounds and their pharmaceutically acceptable
salts can trap IL-1 β and are expected to have utility as therapeutic
agents, for example, for treating cardiovascular disease and inflam-
matory disorders. The disclosure also provides pharmaceutical com-
positions which comprise the compounds disclosed herein or phar-
maceutically acceptable salts thereof. The disclosure also relates to
methods for use of the compounds or their pharmaceutically accept-
able salts in the therapy and prophylaxis of cardiovascular disease
and inflammatory disorders and for preparing pharmaceuticals for
this purpose.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*